Octreotide lar affects the volume of pituitary adenoma in acromegalic patients

What Was Tested

Researchers studied Octreotide in this clinical trial publication.

Who Took Part

According to the abstract, 26 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

26 patients (22 female and 4 male, mean age 57.5±15.0 years) were treated with SSLAR: 5 patients with microadenoma - during 6 months, and 21 patients with macroadenoma - during 12 months before surgery.

How the Study Was Run

A time span of 6 months appears in the methods.

Concentration of hGH and IGF-1 was evaluated at 0, 3, 6 and 12 months, while MRI images were taken at 0, 6 and 12 months prior to surgery.

The volume of pituitary adenoma, estimated as that of an ellipsoid, was based on MRI image projections.

Basic statistics, Shapiro-Wilk and Wilcoxon tests were applied.

What Was Measured

The subject headings attached to it are Acromegaly, Adenoma, Antineoplastic Agents, Hormonal, Growth Hormone-Secreting Pituitary Adenoma, Human Growth Hormone, Insulin-Like Growth Factor I and Neoadjuvant Therapy.

What This Means in Plain Language

This is a clinical trial of Octreotide in 26 patients over 6 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association), a journal based in Germany.

More context: the Octreotide compound page, all human trials.